AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04486352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab - 21 Day Cycle
Description: Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
Study NCT04486352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
Study NCT04486352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
Study NCT04486352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
Study NCT04633759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Exercise
Description: Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
Study NCT05326087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study NCT05326087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA
Description: oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
Study NCT05448703 — intervention group
Intervention type: OTHER
Intervention: Blood Samples for Biomarkers
Description: blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
Study NCT04669899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days
Study NCT04669899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days
Study NCT04919330 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list Control Group
Description: The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
Study NCT05157464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
Study NCT06540859 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.
Study NCT06540859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.
Study NCT06540859 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Non-invasive electrical stimulation of a lower extremity muscle group over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver sham stimulation. The intensity of electrical stimulation will be briefly ramped up to a level at which the participants report perceiving the stimulation (i.e., sensory threshold), then ramped down and turned off for the remainder of the intervention.
Study NCT04486352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
Study NCT06537492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: The REBOA device used in this study will be a computer-aided aortic balloon occlusion catheter with safety feedback and automatic inflation and deflation. The device will be used to temporarily inflate a balloon in the descending aorta through a femoral artery introducer sheath which, when inflated, redirects blood flow to the central circulation.~The REBOA will be inserted into the aorta via the femoral artery through an introducer sheath. Once positioned, the balloon will be inflated to occlude the aorta. The REBOA assistant will be attached to the patient's skin with the adhesive on the underside of the assistant.
Study NCT06537492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-Up Cardiopulmonary Resuscitation (AHUP-CPR)
Description: Conventional CPR will be performed using an automated head and chest elevation device during cardiopulmonary resuscitation (AHUP-CPR).
Study NCT06537492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Chest Compression Device with Active Chest Decompression
Description: In addition to head and thorax elevation, mechanical chest compression will be performed with active chest compression-decompression using a specific mechanical chest compression device.
Study NCT06537492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device
Description: In addition to REBOA, AHUP-CPR and ACD, an impedance threshold device will be used with a dedicated device.
Study NCT05864703 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Instrument-assisted light touch to neck
Study NCT05926336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Study NCT05926336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Study NCT06411626 — intervention group
Intervention type: OTHER
Intervention: PNH-relevant therapies
Description: This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
Study NCT05061667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Paravertebral block for postoperative analgesia in thoracic surgery
Study NCT04540744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of macitentan/tadalafil (10 mg/20 mg)
Description: FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
Study NCT04540744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
Study NCT04540744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Description: Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
Study NCT06344312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yangxue Qingnao Granules
Description: When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
Study NCT06344312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao Granules
Description: When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
Study NCT05061667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Block
Description: Rhomboid block for postoperative analgesia in thoracic surgery
Study NCT06047795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks
Study NCT06047795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy.
Study NCT05166577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat
Description: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week
Study NCT04901754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Apatinib
Description: -Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD.
Study NCT05296681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBT-NM108
Description: Patients receive irinotecan-based chemotherapy per standard of care.
Study NCT05166577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat
Description: Nanatinostat at the confirmed RP2D
Study NCT05166577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir starting at 900 mg orally daily
Study NCT06576804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric cycling training
Description: Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week
Study NCT06576804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric cycling training
Description: Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week
Study NCT05127811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: BION design
Study NCT05252325 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hyaluronic acid plus lidocaine
Description: local injection for correction of nasolabials fold
Study NCT05252325 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hyaluronic acid without lidocaine
Description: local injection for correction of nasolabial folds
Study NCT06509633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education and standard rehabilitation regime
Description: Median nerve gliding exercises, wrist and forearm muscle stretches, wrist mobilizations and finger joint mobilizations
Study NCT06509633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard Rehabilitation regime
Description: standard Rehabilitation regime
Study NCT06331351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: 2 times a day, 1 sachet each time.
Study NCT06331351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea liquid packets
Description: 2 times a day, 1 sachet each time.
Study NCT05651321 — intervention group
Intervention type: OTHER
Intervention: Samples materials of basic taste stimuli and enteral nutrition preparations
Description: Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
Study NCT05166577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
Study NCT05496088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-PVI only
Description: Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation.
Study NCT05496088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-PVI + substrate ablation
Description: Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation.
Study NCT06382467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate + propofol MCT
Description: remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
Study NCT06382467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol MCT
Description: Propofol MCT 2-8 mcg/ml using target-controlled infusion
Study NCT05778149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib,Anlotinib
Description: Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
Study NCT05063019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging and enterography before surgery
Study NCT04737629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancy and Water
Description: In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
Study NCT04737629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Expectancy and Water
Description: Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
Study NCT04737629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Water
Description: Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
Study NCT06154798 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: World Digital Detox Women's Health Program
Description: World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
Study NCT05522998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol (0.4-0.5mg/kg) for anesthesia induction
Study NCT05522998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol(2-2.5mg/kg) for anesthesia induction
Study NCT06096142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solaris DE
Description: Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
Study NCT06217133 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit.~TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage.
Study NCT06096142 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PTA
Description: Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
Study NCT06198153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Cycling
Description: In addition to the conventional physical therapy, children in this group will receive 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks.
Study NCT06198153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Functional Training
Description: In addition to the conventional physical therapy, the training will follow a 6-week progressive functional training program for lower extremities. These exercises will include sit-to-stand exercise, lateral/forward step-up exercise (i.e. climbing a stair or stepping up onto a kerb), and half-knee rise exercise (i.e. rising from the ground). All exercises will be performed in 1-3 sets of 10-15 repetitions, with a 90 second rest in between the sets. Each exercise will be performed within 10-15 minutes. Training session will be given 3 times a week. During the training, intensity will be progressively increased by increasing the repetitions
Study NCT06377813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mode-Kinetic Chain Exercise With Core Stability Exercises
Description: the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
Study NCT06377813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mode-Kinetic Chain Exercise
Description: the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
Study NCT06182111 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative morphine
Description: Morphine dose = 0,1 mg mg/kg (maximum 10 mg) intravenous given 20 min after start of surgery
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
Study NCT04676477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at 40 mg or 80 mg once daily
Study NCT04775680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG106 injection
Description: ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
Study NCT04775680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody injection
Description: PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
Study NCT05073458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisinib
Description: parsaclisib will be administered QD orally
Study NCT05073458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally follwed by Parsaclisinib in the open label period
Study NCT05427669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most